CTNNB1 and neoplasm: Once weekly I.V. administration at 1 mg/kg LNP-CTNNB1 dosage over 6 weeks led to a significant decrease in tumor burden grossly (Fig. 1h–k), and histologically as observed via H&E, Myc-tag, and GS/Ki67 IHC (Fig. 1l; Supplementary Fig. 3e, f).